



Media Releases » **Torrent Pharma announces Q1 FY 2017-18 Results** *July 31st, 2017*

Ahmedabad based Pharmaceuticals major, Torrent Pharmaceuticals Limited, today released its financial results for the Quarter ended 30th June 2017.

Quarterly Financials

- For Q1 FY 2017-18 revenues were at Rs. 1,374 crores as against Rs. 1,551 crores during the same period last year.
- EBIDTA for Q1 FY 2017-18 was at Rs. 400 crores as against Rs. 462 crores during the same period last year.
- PAT for Q1 2017-18 was at Rs. 188 crores as against Rs.292 crores during the same period last year.
- Previous period include exceptional revenues and profits which was primarily on account of the launch of a new product in US market, which had limited competition.
- Research and development spend during the Q1 FY 2017-18 was Rs 101 crores as against Rs 90 crores during the same period last year.

Q1 PERFORMANCE HIGHLIGHTS

India Business

- Domestic formulation business recorded revenues of Rs. 464 crores for Q1 FY 2017-18 v/s Rs. 510 crores for the same period last year. The Indian pharmaceuticals industry got impacted due to reduction in channel inventory during transition to Goods and Services Act and consequently the India business performance also got impacted during the quarter.

Brazil Business

- Brazilian business recorded revenues of Rs. 181 crores for Q1 FY 2017-18 v/s Rs. 167 crores for the same period last year, showing 8% growth.

USA

- US business recorded revenues of Rs. 272 crores for Q1 FY 2017-18 v/s Rs. 434 crores for the same period last year.
- Previous period include exceptional revenues, primarily on account of the launch of a new product which had limited competition.
- 1 ANDA were filed during the quarter. 3 tentative approvals are received and 26 ANDAs are pending approval as on 30th June 17.

Germany

- German business recorded revenues of Rs. 202 crores for Q1 FY 2017-18 v/s Rs. 187 crores for the same period last year, showing 8% growth.

About Torrent Pharma

Torrent Pharma, with annual revenues of more than Rs. 5800 crores is the flagship Company of the Rs. 18,300 crore Torrent Group.

Torrent Pharma continues to be at the forefront of the Indian pharmaceutical industry with many of its products ranking among the top 500 brands (AIOCD Dataset) in India. Its widespread international presence also includes several markets where Torrent is amongst the leading pharmaceutical companies in the respective countries.

Torrent has a fully equipped Research Center, employing almost 900 scientists, to support the Company's operations and product pipeline for both Domestic and Overseas markets. The Company's manufacturing plants located at Indrad, Baddi, Sikkim, Dahej, Pithampur and Vizag have facilities to produce Formulations and Bulk drugs. The plants are approved by authorities from various regulated and semi regulated markets like US, UK, Brazil, Germany, Australia and South Africa.